Trial Profile

Open-Label Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Chronic Urticaria

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 18 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Briquilimab (Primary)
Indications Chronic urticaria; Cold Urticaria
Focus Adverse reactions
Sponsors Jasper Therapeutics

Most Recent Events

12 May 2025 According to a Jasper Therapeutics media release, the additional data from this study will be presented in the first half of Q3 2025.
27 Feb 2025 According to a Jasper Therapeutics media release, results from approximately 40 additional patients in the BEACON study and SPOTLIGHT study, as well as results from approximately 30 patients in the open-label extension study will be presented in mid year 2025.
21 Dec 2024 Status changed from planning to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com